IRA, non-interference, drug shortages, prescription drug access and affordability, transparency, insulin policy, drug pricing in federal programs
2025 · 3rd Quarter (July 1 - Sep 30)
ELI LILLY AND COMPANY
Filed by TARPLIN, DOWNS & YOUNG, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 16, 2025
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- TARPLIN, DOWNS & YOUNG, LLC
- Client
- ELI LILLY AND COMPANY
- Filing UUID
- c3fde9c7-80fd-4cd1-968c-cef315db8730
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Medicare & Medicaid payment and coverage issues, Medicare Part D, Medicare Part B, drug pricing in federal programs
federal budget issues
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.